Premium
Tibolone and low‐dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability
Author(s) -
Hammar ML,
Van De Weijer P,
Franke HR,
Pornel B,
Von Mauw EMJ,
Nijland EA
Publication year - 2007
Publication title -
bjog: an international journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.157
H-Index - 164
eISSN - 1471-0528
pISSN - 1470-0328
DOI - 10.1111/j.1471-0528.2007.01537.x
Subject(s) - tibolone , medicine , tolerability , vasomotor , norethisterone , vaginal bleeding , norethisterone acetate , adverse effect , menopause , metrorrhagia , randomized controlled trial , gynecology , population , pregnancy , environmental health , biology , family planning , research methodology , genetics
Objectives The primary objective was to compare the vaginal bleeding pattern during administration of tibolone and low‐dose continuous combined estradiol plus norethisterone acetate (E 2 /NETA). The secondary objectives were efficacy on vasomotor symptoms and vaginal atrophy. Design A randomised, double‐blind, double‐dummy, group comparative intervention trial. Setting Multicentre study executed in 32 centres in 7 European countries. Sample Five hundred and seventy‐two healthy symptomatic postmenopausal women, aged 45–65 years. Methods Participants were randomised to receive 2.5 mg tibolone or 1 mg 17β estradiol plus 0.5 mg norethisterone acetate (E 2 /NETA) daily for 48 weeks. Main outcome measures Prevalence of vaginal bleeding, hot flushes and adverse events. Results The incidence of bleeding was significantly lower in the tibolone group during the first 3 months of treatment (18.3 versus 33.1%; P < 0.001) when compared with the E 2 /NETA group. This effect on the bleeding pattern was sustained throughout the study, although reaching statistical significance again only in 7–9 months of treatment (11 versus 19%; P < 0.05). In both treatment groups, vasomotor symptoms and vaginal atrophy were significantly reduced to a similar extent when compared with baseline. The prevalence of breast pain/tenderness was significantly lower with tibolone compared with E 2 /NETA (3.2 versus 9.8%; P < 0.001). Conclusion Tibolone reduces menopausal symptoms to a similar extent as conventional low‐dose continuous combined hormone therapy but causes significant less vaginal bleeding in the first 3 months of treatment. This constitutes an important argument for woman adherence to therapy.